Ferret islet amyloid polypeptide (IAPP): Characterization of in vitro and in vivo amyloidogenicity

Novo Nordisk A/S, Novo Nordisk Park, Måløv, Denmark.
Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis (Impact Factor: 2.01). 11/2011; 18(4):222-8. DOI: 10.3109/13506129.2011.627956
Source: PubMed


Diabetes in the domestic ferret (Mustela putorius furo) has previously been described and the purpose of this study was to evaluate if the ferret could serve as a model for the study of β-cell degeneration associated with formation of islet amyloid. The nucleotide and amino acid sequence of ferret islet amyloid polypeptide (IAPP) 1-37 was identified and the synthesized peptide was studied with regards to in vitro amyloidogenicity and potential cellular toxicity in a comparative approach to human, cat and the nonamyloidogenic rat IAPP. Ferret IAPP forms amyloid-like fibrils, but with a longer lag phase than human and cat IAPP and the aggregation process was shown to reduce cell viability of cultured β-cells, but with less potency than these two amyloidogenic counterparts. Immunohistochemistry of ferret pancreas confirmed IAPP expression in the islets of Langerhans, but no islet amyloid was found in a very limited sample size of one diabetic and five healthy ferrets. Islet amyloid has never been described in ferrets, and it is not possible to determine if it is due to lack of studies/material or to the fact that the ferret's life span is too short to present with such pathology.

Download full-text


Available from: Marie-Odile Benoit-Biancamano, Feb 11, 2015
  • Source
    • "Amyloid can be detected in the islets of Langerhans in a majority of human and feline diabetes patients and it is also commonly seen in islet cell tumors in human and dogs (O'Brien et al., 1990; Kelley et al., 1996; Paulsson et al., 2011). It is identified as densely packed protein deposits with a very characteristic fibrillar ultrastructure; these deposits origin from islet amyloid polypeptide (IAPP). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Herein, we report a 25-year-old male polar bear suffering from a pancreatic islet cell tumor. The aim of this report is to present a case of this rare tumor in a captive polar bear. The implication of potential risk factors such as high carbohydrate diet or the presence of amyloid fibril deposits was assessed. Necropsy examination revealed several other changes, including nodules observed in the liver, spleen, pancreas, intestine, and thyroid glands that were submitted for histopathologic analysis. Interestingly, the multiple neoplastic nodules were unrelated and included a pancreatic islet cell tumor. Immunohistochemistry of the pancreas confirmed the presence of insulin and islet amyloid polypeptide (IAPP) within the pancreatic islet cells. The IAPP gene was extracted from the paraffin-embedded liver tissue and sequenced. IAPP cDNA from the polar bear exhibits some differences as compared to the sequence published for several other species. Different factors responsible for neoplasms in bears such as diet, infectious agents, and industrial chemical exposure are reviewed. This case report raised several issues that further studies may address by evaluating the prevalence of cancers in captive or wild animals. Zoo Biol. XX:XX–XX, 2014. © 2014 Wiley Periodicals, Inc.
    Full-text · Article · Sep 2014 · Zoo Biology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes Mellitus is a metabolic disorder that is characterized by high blood glucose because of the insulin-resistance and insulin-deficiency in Type 2,while the insulin deficiency due to destruction of islet cells in the pancreas in Type 1 . The development of type 2 diabetes is caused by a combination of lifestyle and genetic factors. Aging patients with diabetes are at increased risk of developing cognitive and memory dysfunctions,which is one of the significant symptoms of Alzheimer Disease(AD). Also, over 2/3 of AD patients were clinically indentified with impairment of glucose. Cognitive dysfunction would be associated with poor self-care ability in diabetes patients.This review will briefly summarize the current knowledge of the pathogenesis of these two diseases and highlight similarities in their pathophysiologies .Furthermore, we will shortly discuss recent progress in the insulin-targeted strategy, aiming to explore the inner linkage between these two diseases in aging populations.
    No preview · Article · May 2013 · Experimental gerontology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Deposition of islet amyloid has been associated with beta-cell death, thereby furthering diabetes progression. Several hypoglycemic agents, such as thiazolidinediones, biguanide and dipeptidyl peptidase-4 inhibitors, have been known to preserve beta-cell mass, possibly by direct inhibition of islet amyloid formation. The general objective of this study was to evaluate the impact of the major representatives of hypoglycemic agents on amyloid formation by using in vitro molecular screening approaches. Ten prototypical representatives of hypoglycemic agents were evaluated for the inhibition of amyloid formation in vitro using thioflavin fluorescence assays, far-ultraviolet circular dichroism, photo-induced cross linking assays and cell viability assays. Glyburide, repaglinide and troglitazone showed the highest potency in delaying and reducing fibril formation. Troglitazone, a thiazolidinedione, was the most effective agent abrogating amyloid fibril formation. Troglitazone affected the secondary structures of incubated human islet amyloid polypeptide (hIAPP). The circular dichroism spectra showed a delayed transition to the beta sheet conformation. A photo-induced cross-linking-based oligomerization assay demonstrated that repaglinide supressed the formation of hIAPP oligomers, whereas glyburide and troglitazone were ineffective in inhibiting oligomerization. Cell toxicity induced by hIAPP was reduced by all 3 compounds. This study provides new insights that could potentially identify new therapeutic strategies to impede the progression of pancreatic amyloidosis in human patients with type 2 diabetes. Copyright © 2015 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.
    Full-text · Article · Apr 2015 · Canadian Journal of Diabetes
Show more